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(57) ABSTRACT 
Methods and apparatus for analyzing the chemical compo 
sition of vulnerable plaques With an intravascular catheter 
having a near-infrared light source, a ?ber-optic probe, a 
mechanism for directing the light from the light source into 
a blood vessel, and detectors for detecting light re?ected or 
scattered by the tissue. The light source may be a tunable 
laser, and may transmit an incident beam having a Wave 
length ranging from 1400 to 4100 nm. A computer may be 
included to receive and process the spectral data in the 
analysis of the vulnerable plaques. Acatheter system may be 
con?gured to provide near-IR spectrometric imaging of 
arteries to non-destructively locate and determine lipid pool 
and ?brous cap size and composition. Additionally, media 
tors and cellular components may be also determined that 
are typically associated With vulnerable plaques Which have 
an increased risk of rupture. The lipid pool, ?brous cap, and 
in?ammatory response may serve as an in vivo marker for 
vulnerable atherosclerotic plaques. Methods are further pro 
vided for prospectively identifying and characterizing vul 
nerable plaques Which may include the steps of focusing 
near-IR light onto a blood vessel Wall; detecting the scat 
tered light in the region; and analyzing the resulting spectra 
across the full preselected Wavelength range, particularly in 
the ranges that include identifying peaks for vulnerable 
plaque constituents. 
15 Claims, 9 Drawing Sheets 
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METHODS AND APPARATUS FOR IN VIVO 
IDENTIFICATION AND 
CHARACTERIZATION OF VULNERABLE 
ATHEROSCLEROTIC PLAQUES 
This application is a continuation (and claims the bene?t 
of priority under 35 USC 120) of US. application Ser. No. 
09/169,621, ?led Oct. 8, 1998 noW abandoned. The disclo 
sure of the prior application is considered part of (and 
incorporated by reference in) the disclosure of this applica 
tion. 
FIELD OF THE INVENTION 
The present invention relates to the ?eld of atherosclerosis 
intervention. More speci?cally, the invention relates to near 
infrared imaging for in vivo identi?cation and characteriZa 
tion of tissue including vulnerable atherosclerotic plaques. 
BACKGROUND OF THE INVENTION 
Over the past tWo decades, valuable studies have been 
conducted using neW intracoronary technologies to charac 
teriZe coronary lesions in living patients. These neW tech 
nologies include angioscopy, ultrasound, and atherectomy. 
Studies based upon these approaches have further added to 
the knoWledge gained from post-mortem studies. While 
much has been learned during post-mortem studies, by 
de?nition, these investigations cannot provide prospective 
data. Furthermore, the procedures used in living patients, 
cannot usually provide detailed information on the chemical 
composition of the diseased tissue. A signi?cant amount of 
relevant information, hoWever, has been derived over the 
years through various studies on coronary lesions. 
The characteriZation of lesions causing acute coronary 
syndromes has been advanced signi?cantly by post-mortem 
observations. It Was earlier observed that in human autopsy 
specimens of thrombosed coronary arterial segments, the 
thrombus Was situated at the site of a plaque Where an 
intimal fracture alloWed the exposure of soft, abscess-like 
lipoid material into the lumen of the blood vessel 
(Constantinides P, Plaque ?ssures in human coronary 
thrombosis, J Atheroscler Res 1966; 6:1—17 (cited refer 
ences are incorporated herein by reference)). Subsequently, 
it Was shoWn that coronary thrombi responsible for fatal 
myocardial infarction Were almost exclusively found at the 
site of disrupted plaques (Davies M J, Thomas A C, Throm 
bosis and acute coronary artery lesions in sudden cardiac 
ischemic death, N Engl J Med 1984; 310:1137—40; Davies 
M J, A macro and micro vieW of coronary vascular insult in 
ischemic heart disease, Cir 1990; 82(3):38—46; Falk E, 
Plaque rupture With severe pre existing stenosis precipitating 
coronary thrombosis: Characteristics of coronary atheroscle 
rotic plaques underlying fatal occlusive thrombi, Br Heart 
1983; 50:127—34). The lipid content of human aortic plaques 
displaying ulceration and thrombosis Was observed to be 
greater than that of non-disrupted plaques. Similarly, in 
patients dying of acute myocardial infarction, previous 
research revealed that While culprit lesion morphology in 
myocardial infarction is heterogeneous With respect to 
plaque architecture and cellular composition (van der WalA 
C, Becker AE, van der Loos C M, Das P K, Site of intimal 
rupture or erosion of thrombosed coronary atherosclerotic 
plaques is characteriZed by an in?ammatory process irre 
spective of the dominant plaque morphology, Circulation 
1994; 89:36—44), the immediate site of plaque rupture is 
marked by an in?ammatory process. An incidence of plaque 
disruption of about 83% has been also reported, similar to 
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that of infarction, in patients With unstable angina. Addi 
tional reports noted the occurrence of coronary thrombosis 
at sites that do not shoW typical signs of plaque rupture 
(Burke A P, Farb A, Malcom G T, Liang Y-H, Smialek J, 
Virmani R, Coronary risk factors and plaque morphology in 
men With coronary disease Who died suddenly, N Engl J 
Med 1997; 336:1276—82). These have been termed sites of 
erosion, and it is estimated that they are responsible for 
approximately 30% of coronary thrombi, With plaque rup 
ture accounting for the remainder. There is a frequent 
occurrence in these studies of lipid-rich plaques With thin 
caps, both ruptured and non-ruptured, as incidental ?ndings 
in patients dying of other coronary lesions, or non-cardiac 
causes (Falk E, Shah P K, Fuster V, Coronary plaque 
disruption, Circ. 1995; 92:657—71). It has also been 
observed that approximately 80% of patients dying suddenly 
had such lesions in addition to their culprit lesions (Farb A, 
Burke A P, Tang A L et al, Coronary plaque erosion Without 
rupture into a lipid core: A frequent cause of coronary 
thrombosis in sudden coronary death, Circulation 1996; 
93:1354—63). Although many post-mortem studies have 
yielded valuable information, there are several important 
limitations to their use. Because of possible selection bias, 
the ?ndings derived from autopsy studies can be generaliZed 
With certainty only to those Who die of acute coronary 
syndromes. It is quite possible that the prevalence, nature, 
and degree of plaque disruption and/or associated thrombo 
sis of culprit lesions, is different in those surviving the 
disease. Results from autopsy studies suggest nonetheless 
that most acute lesions arise from a plaque that includes a 
lipid pool, a thin cap, and macrophage in?ltration. While 
prospective studies have been limited, these histologic fea 
tures may be considered to represent a “vulnerable plaque”, 
a term ?rst de?ned by Muller et al (Muller J E et al, Triggers, 
Acute Risk Factors and Vulnerable Plaques: The Lexicon of 
a NeW Frontier, JACC 1994; 23(3) 809—13). This type of 
plaque refers to its functional property of having an 
increased likelihood of rupture, and may include more than 
one histologic type. 
The coronary angiogram is considered a primary source 
of information for living patients With lesions that cause 
acute coronary syndromes. Recently, retrospective analysis 
of coronary angiograms in patients Who subsequently devel 
oped unstable angina and myocardial infarction demon 
strated that many culprit lesions originate from plaques 
previously causing less than 50% stenosis (Ambrose J A, 
Tannenbaum M A, Alexopoulos D et al, Angiographic 
progression of coronary artery disease and the development 
of myocardial infarction, J Am Coll Cardiol 1988; 12, 56-62; 
Ambrose J A, Winters S L, Arora R R et al, Angiographic 
evolution of coronary artery morphology in unstable angina, 
J Am Coll Cardiol 1986; 5,472—8; Nobuyoshi M, Tanaka M, 
Nosaka H et al, Progression of coronary atherosclerosis: is 
coronary spasm related to progression? J Am Coll Cardiol 
1991; 18, 904—10; Little W C, DoWnes T R, Applegate R J, 
The underlying coronary lesion in myocardial infarction: 
implications for coronary angiography, Clin Cardiol 1991; 
14, 868—74). The residual stenosis, after successful throm 
bolytic therapy, Was found to be of only moderate severity 
in many cases, supporting the concept that occlusive throm 
bus frequently develops at coronary sites Without prior 
severe stenosis (Kereiakes D J, Topol E J, Sea G, Myocardial 
infarction With minimal coronary atherosclerosis in the era 
of thrombolytic reperfusion, J Am Coll Cardiol 1991; 17, 
304—12; BroWn G G, Gallary C A, Badger R S et al, 
Incomplete lysis of thrombus in the moderate underlying 
atherosclerotic lesion during intracoronary infusion of strep 
US 6,816,743 B2 
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tokinase for acute myocardial infarction, Circulation 1986; 
73, 653—61). Despite these advances, the use of coronary 
angiography to study coronary atherosclerotic lesions in 
living patients has severe limitations including its inability 
to provide information about the sub-surface features of the 
plaque. The relatively loW sensitivity and speci?city of a 
plaque’s geometric surface features to predict subsequent 
occlusion indicate that other plaque-related characteristics 
(i.e., plaque composition), not detectable by angiography, 
may be more important in the determination of plaque 
vulnerability (Taeymans Y, Theroux P, Lesperance J, Waters 
D, Quantitative angiographic morphology of the coronary 
artery lesions at risk of thrombotic occlusion, Circulation 
1992; 85, 78—85). 
The development of angioscopic imaging devices for the 
coronary arteries also provided a valuable opportunity to 
de?ne the surface features of lesions Which cause unstable 
angina and acute coronary syndromes. Angioscopic imaging 
devices Were used percutaneously to obtain a clear vieW, 
With magni?cation, of the inner surface of the coronary 
lumen in patients undergoing catheteriZation. Normal seg 
ments of coronary arteries in living patients Were observed 
to be White and smooth, While disrupted atherosclerotic 
plaques causing disease Were elevated and, in many cases, 
yelloW and/or red in color (MiZuno K, Miyamoto A, Sato 
mura K et al, Angioscopic coronary macromorphology in 
patients With acute coronary disorders, Lancet 1991; 337, 
809—12). Imaging of the site of percutaneous transluminal 
coronary angioplasty (PTCA) also permitted identi?cation 
of the mechanism of abrupt closure (SassoWer M A, Abela 
G S, Koch J M et al, Angioscopic evaluation of peri 
procedural and post-procedural abrupt closure following 
percutaneous coronary angioplasty, Am Heart J 1993). A 
study using angioscopy demonstrated that patients With 
“glistening yelloW” plaques had a 68% incident rate Within 
the subsequent year of unstable angina or myocardial 
infarction, as opposed to a 4% in those Without such lesions 
(Uchida et al, Prediction of acute coronary syndromes by 
percutaneous coronary angioscopy in patients With stable 
angina, Amer Heart J 1995, 130 (2): 195—203). Despite the 
obvious advantages of imaging the interior of a coronary 
artery, the angioscope can only generally provide informa 
tion about the shape and color of the interior surface of the 
blood vessel. The technique also requires a period of coro 
nary occlusion and an experienced team for safe perfor 
mance. The interpretation of ?ndings With terms such as 
“glistening yelloW” are particularly subjective and may 
provide inconsistent results. 
Intracoronary ultrasound devices have been also used to 
characteriZe coronary lesions. It is possible to identify 
certain characteristics of these lesions beneath their intimal 
surface. The ability of intravascular coronary ultrasound 
(ICUS) to identify tissue characteristics of lesions has been 
established in in vitro studies With histologic correlation 
(Tobis J M, Mahon D, Moriuchi M et al, Intravascular 
ultrasonic imaging, Tex Heart Inst J 1990; 17, 181—9; Tobis 
J M, Mallery J, Mahon Dea, Intravascular ultrasound imag 
ing of human coronary arteries in vivo: Analysis of tissue 
characteriZations With comparison to in vitro histologic 
specimens, Circ. 1991; 83, 913—26). Fibrous plaques pro 
duce bright images With echo-free shadoWing. Plaques With 
extracellular lipid or necrotic material displayed minimal 
re?ectivity typically appearing in the form of hypoechoic 
areas, but differentiation from thrombus is quite often dif 
?cult. Such correlation studies have led to Widespread use of 
the terms “hard” or “soft” to characteriZe lesions based on 
these ultrasonic images (Hodgson J M, Reddy K G, Suneja 
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R, Nair R N, Lesnefsky E J, Sheehan H M, Intracoronary 
ultrasound imaging: correlation of plaque morphology With 
angiography, clinical syndrome, and procedural results in 
patients undergoing coronary angioplasty, J Am Coll Cardiol 
1993; 21, 35—44; Nissen S E, Gurley J C, Booth D C, 
McClure R R, Berk M R, DeMaria A N, Spectrum of 
intravascular ultrasound ?ndings in atherosclerosis: Wall 
morphology and lumen shape in CAD patients, J Am Coll 
Cardiol 1991; 93; Nissen S E, Gurley J C, Grines C L, Booth 
D C, McClure R, Berk M, Intravascular ultrasound assess 
ment of lumen siZe and Wall morphology in normal subjects 
and patients With coronary artery disease. Circ. 1991; 84, 
1087—99). Unfortunately, the sensitivity and speci?city of 
ICUS to identify particular components of a lesion, includ 
ing lipid-rich regions With thin caps, is limited by the 
resolution of ICUS technology, and its further inability to 
identify chemical composition of subject tissue. 
The performance of atherectomy procedures further pro 
vided signi?cant information relating to coronary lesions. 
For example, in a study of atherectomy specimens in living 
patients With stable and unstable coronary syndromes 
(Moreno P R, Falk E, Palacios I F, NeWell J B, Fuster V, 
Fallon J T, Macrophage in?ltration in acute coronary syn 
dromes: Implications for plaque rupture, Circulation 1994; 
90:775—8), it Was shoWn that macrophage-rich areas are 
more frequently found in patients With unstable angina and 
non-Q Wave myocardial infarction, and are a marker of 
unstable atherosclerotic plaques. More recently, macroph 
ages have been identi?ed as a major source of tissue factor 
establishing a cell-mediated thrombogenicity in unstable 
atherosclerotic plaques (Moreno P R, Bernardi V H, LopeZ 
Cueller J et al, Macrophages, smooth muscle cells and tissue 
factor in unstable angina: Implications for cell-mediated 
thrombogenicity in acute coronary syndromes, Circulation 
1996; 94:3090—7). There are hoWever several limitations to 
the use of atherectomy specimens to study vulnerable coro 
nary plaques. The technique is no longer in frequent use for 
clinical purposes, and it is anticipated that many plaques 
causing disease Will not be stenotic, and hence cannot be 
sampled by atherectomy performed for clinical indications. 
Sampling errors may also occur if only the super?cial aspect 
of the plaque is retrieved Which obscure anatomic relation 
ships With the rest of the plaque. 
Other techniques for analyZing coronary lesions have 
been also proposed. Recent approaches for identi?cation of 
vulnerable plaque, for example, include thermography, 
ultra-fast CT, magnetic resonance imaging (MRI) and opti 
cal coherence tomography (OCT) (BreZinski M E, Tearney 
G J, Bouma B E et al, Optical coherence tomography for 
optical biopsy. Circulation 1996; 93:1206—13; BreZinski M 
E, Tearney G J, Weissman N J et al, Assessing atheroscle 
rotic plaque morphology: Comparison of optical coherence 
tomography and high frequency intravascular ultrasound, 
Heart 1996; 77:397—403; Toussaint J -F, LaMuraglia GMSJF, 
Fuster V, Kantor H L, Magnetic resonance images lipid, 
?brous, calci?ed, hemorrhagic, and thrombotic components 
of human atherosclerosis in vivo, Circ. 1996; 94:932-8). 
Each of these approaches exhibit some relative strengths and 
limitations. For example, thermography has not yet been 
validated in vivo, and ultrafast CT is an excellent Way to 
detect calcium but other ions and compounds are not 
detected. MRI is generally not suited for imaging of the 
small, moving coronary arteries, as opposed to the relatively 
siZable carotids. OCT can provide images but has not yet 
been reported to obtain images through blood. The limita 
tions of these techniques for analyZing arterial diseases 
preclude their useful and practical application for clinical 
purposes. 
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It has been generally observed that atherosclerosis, With 
out associated thrombosis, is often an innocuous and asymp 
tomatic disease. Many patients With atherosclerosis can be 
treated surgically or by drugs With high initial success, and 
often have a favorable long-term prognosis. The acute 
manifestation of atherosclerosis, commonly occurring as 
myocardial infarction, unstable angina, or sudden death, 
usually arises When thrombus develops. These serious 
events typically develop at the site of plaque ?ssure or 
rupture. A number of studies have demonstrated that plaque 
rupture plays a pivotal role in the pathophysiology (the 
physiology of abnormal states and the functional changes 
that accompany a particular syndrome or disease) of acute 
coronary syndromes. Recent research indicates that it is 
often not the severity of stenosis (a narroWing or constriction 
of the diameter of an artery by plaque volume) that deter 
mines a potential outcome. It is more often the type of 
stenosis, or the chemical composition of the plaque, and the 
extent of collateral groWth Which becomes a determining 
factor. The kind of plaque, determined by composition, 
consistency, vulnerability and thrombogenicity, varies 
greatly from patient to patient, even from plaque to plaque 
in different locations, and there is no simple relation among 
plaque kind, plaque volume or stenosis severity. 
Near-IR spectrometry has been performed in a limited 
number of applications for analyZing and detecting the 
presence of knoWn indicators associated With a particular 
disease or condition. For example, lipids have been exam 
ined With near-IR in vitro and in vivo in gerbil brains 
folloWing experimentally induced stroke, and provided the 
identi?cation of nine different saturated and unsaturated 
fatty acids found in the gerbil brain. The changes in Water 
content related to edema and changes in proteins Were also 
monitored non-invasively by near-IR spectrometry in these 
studies. Near-IR spectrometry has also been used to analyZe 
HDL, LDL, and cholesterol in the blood vessels of rats, and 
has been performed With ?ber-optic probes to determine fat 
content in meats commercially (Nagao A, UoZumi J, IWa 
moto M, YamaZaki M, Determination of fat content in meats 
by near-infrared re?ectance spectroscopy, Chem Abstr 1985; 
219697r), and to determine total body lipids in humans 
non-invasively (ConWay J, Norris K, BodWell C, A neW 
approach for the estimation of body composition: Infrared 
interactance, Amer J Clin Nutr 1984; 1123). In addition, 
near-IR imaging has been used in human stroke patients to 
analyZe atherosclerotic plaque by identifying and locating 
oxidiZed lipoprotein spectral signatures. A near-IR imaging 
system and parallel vector supercomputer has been used 
With a ?ber-optic probe to produce chemical maps of the 
intimal surface of living arteries. Spectrometric data col 
lected at hundreds of near-IR Wavelengths Were assembled 
into color pictures of the lipoprotein and apolipoprotein 
composition of early atheromas using a vectoriZed 3-D 
cellular automaton-based algorithm that operates in parallel. 
The nonparametric mathematics developed to identify and 
quantify the constituents of each voxel in the artery Wall 
avoided the matrix factoriZation that generates excess error 
in other pattern recognition methods, and permitted analysis 
in a Wavelength space of over 1000 dimensions using feWer 
than 100 calibration samples. Asurface feature resolution of 
5.5 micrometers and depth resolution of 6.5 micrometers 
Were achieved With the system. Controlling the apertures on 
?ber-optic probes permitted the three-dimensional relation 
ships betWeen sample components to be determined. Data 
from the ?ber-optic probe con?rmed the injury hypothesis of 
lesion formation and the differing roles of HDL and LDL in 
cholesterol transport. Additionally, near-IR spectrometry has 
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been used trans-arterially on exposed carotid arteries in 
living patients undergoing endarterectomy. Images Were 
obtained of ?brous cap, lipids, thrombus, ulceration and 
necrosis With an indium antimonide focal plane array video 
camera (Dempsey R J, Cassis LA, Davis D G, Lodder R A, 
Near-infrared Imaging and Spectroscopy in Stroke 
Research: Lipoprotein Distribution and Disease, Ann. NY. 
Acad. Sci. 1997; 820:149—69). It has been observed that 
near-IR spectral analysis has chemical imaging ability, and 
further provides useful information and detail relating to 
various internal body structures such as muscle, bone, and 
arteries (Van de Van M, French T, Fishkin J, Gratton F, 
Near-infrared imaging spectroscopy of mammalian tissue in 
the frequency domain. Biophys J 1991; 167a). Near-IR 
Raman spectroscopy has been also used recently to quanti 
tatively analyZe the lipid component of human atheroscle 
rotic plaques (Weinmann et al, Quantitative analysis of 
cholesterol and cholesteryl esters in human atherosclerotic 
plaques using near-infrared Raman spectroscopy, Athero 
sclerosis 1998; 140(1), 81—8) and may provide vibrational 
information on chemical structures Without penetration of 
more than a feW microns of Water or blood. While Raman 
spectroscopy may provide some analysis of plaque under 
certain test conditions, many technical dif?culties including 
its inherent inef?ciency prevent or limit its broad application 
in living patients through catheter-based systems. The per 
formance of Raman spectroscopy through a catheter is also 
believed to be a time-consuming and inherently inef?cient 
process that fails to provide accurate quanti?cation of plaque 
constituents. 
SUMMARY OF THE INVENTION 
The present invention provides reliable methods and 
apparatus for detecting and analyZing the composition of 
vulnerable plaques in living tissue With near-infrared (IR) 
radiation. The invention, in a non-destructive manner, may 
provide early detection of vulnerable plaques before the 
onset of an acute syndrome. Near-IR spectroscopy, a variant 
of the procedure used to determine the chemical composi 
tion of extraterrestrial rock samples, may identify plaques 
With a lipid pool and thin cap in vivo. In accordance With the 
invention, this may be performed through a near-IR coro 
nary catheter for identifying vulnerable plaques in the coro 
nary arteries of living patients. The small risk to patients 
associated With near-IR imaging Will be balanced against the 
possible bene?ts of improved risk-strati?cation and effective 
therapy. 
Another object of the present invention is to provide a 
method and apparatus speci?cally adapted to identify vul 
nerable plaques to thereby alloW physicians to prescribe 
appropriate drugs that are more likely to provide effective 
treatment. This is a particularly important consideration 
When it is realiZed that some of the drugs or devices 
prescribed to treat lesions may have serious side effects 
Which may, in some instances, be avoided altogether. Still 
another object of the invention is to provide a method and 
apparatus Wherein infrared radiation of a Wavelength range 
from about 1400—4100 nm, and more preferably from about 
1600—1800 nm, is sequentially focused onto selected arterial 
endothelium. The re?ected or scattered infrared radiation 
may be then detected and analyZed at high speed in accor 
dance With the invention to not only identify vulnerable 
plaques, but to also evaluate the progression of disease and 
effectiveness of treatment. 
In accordance With the principles of the present invention, 
improved near-IR imaging apparatus may be provided for 
analyZing vulnerable plaques The apparatus may not be only 
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utilized for in vitro analysis, but may also be advantageously 
utilized for in vivo analysis. The apparatus may comprise a 
light source for transmitting simultaneously and in parallel 
an incident beam of light of a Wavelength range from 
approximately 1400 to 4100 nm, and more preferably Within 
a “Water WindoW” such as from about 1600 to 1800 nm or 
around 2080 nm. A ?ber-optic probe may be operatively 
connected to the light source, and a light directing or 
focusing mechanism may be mounted to the distal end of the 
probe. The focusing mechanism may comprise a compound 
parabolic concentrator (CPC) that may, for example, be 
formed from plastic and include a polished aluminum lining. 
The CPC is similar to those designed for use for solar poWer 
concentration. In particular, the CPC may be adapted to 
compress the incident beam from the transmitting ?ber-optic 
onto a small spot on the tissue surface undergoing analysis. 
Additionally, the apparatus may include detectors such as 
lead sul?de detectors for detecting the scattered light from 
the artery surface or other tissue being analyzed. In an 
alternative embodiment, the light directing mechanism com 
prises an inverted, substantially conical re?ector developed 
from both ellipsoids of rotation and paraboloids of rotation. 
This re?ector may direct the incident beam from the trans 
mitting optic ?ber over the tissue undergoing analysis. 
Additionally, light re?ected or scattered by the tissue is 
directed or focused into receiving optic ?bers so as to alloW 
for better detection and hence, chemical analysis of the 
tissue. The ?ber-optic catheter may also comprise separate 
bundles of ?bers to inject light into the vessel Wall at one 
location, and detect light scattered through the plaque and 
vessel Wall at another location. The light injection and 
detection ports may be placed in contact With the vessel Wall 
using a balloon or other device during the measurement and 
therapeutic processes. A portion of the transmitting ?bers 
may also be directed onto a re?ectance standard at the 
catheter tip and returned to a detector module for use in 
absorbance ratios. The apparatus may further include suit 
ably sized catheters and equipment for high speed parallel 
analyzing of the spectra re?ected from the tissue, and 
producing color images thereof. Such equipment may, for 
example, include a computer such as a supercomputer used 
at the University of Kentucky, and appropriate softWare such 
as the copyrighted Bootstrap Error-Adjusted Single-Sample 
Technique (BEST) Algorithm softWare program developed 
by Robert A. Lodder. Further, the ?ber-optic probe may be 
preferably adapted for introduction into a patient to thereby 
alloW in vivo analysis of artery Walls, or in particular, lesions 
Which may characterized as vulnerable plaques. Additional 
information relating to these and other applications of the 
present invention may be further described in US. Pat. No. 
5,441,053 (APPARATUS AND METHOD FOR MUL 
TIPLE WAVELENGTH ANALYSIS OF TISSUE) Which is 
incorporated by reference herein. 
A further aspect of the present invention provides various 
methods of analyzing arterial lesions With near-IR spectros 
copy for the existence of vulnerable plaque characteristics. 
The method may include the steps of focusing light on the 
tissue to be analyzed, and detecting light re?ected by the 
tissue. The light being focused may have a Wavelength 
ranging from approximately 1400 to 4100; and more pref 
erably 1600 to 1800 nm. The method may further include a 
step of analyzing the spectra from the tissue and producing 
color images thereof. Advantageously, both the focusing and 
analyzing steps may be performed to alloW high speed data 
acquisition and analysis. Speci?cally, light having a range of 
Wavelengths from 1400 to 4100 nm, and more preferably 
from 1600 to 1800 nm, may be simultaneously focused in 
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parallel at all locations being analyzed. The analysis of the 
re?ected light may be also completed simultaneously and in 
parallel for all locations being analyzed over the same range 
of Wavelengths. As all tissues absorb light at all these 
Wavelengths, With different tissues absorbing only a little 
more at some Wavelengths than others, this broad band 
parallel approach may be useful to reduce the risk of missing 
unusual tissue during study. Hence, the analysis may be 
more accurate and complete. When identifying peaks for 
particular lipids and cholesterol Which are knoWn to occur at 
certain ranges or Water WindoWs, the analysis may be 
modi?ed in accordance With the invention to more readily 
detect and identify the existences of vulnerable plaques. 
Furthermore, as the focusing of near-IR radiation and analy 
sis are performed in parallel, the complete study may still be 
completed in a suf?ciently short time span to alloW clinical 
utilization as With arterial angiography. In accordance With 
a further method of analyzing arterial endothelium in vivo 
utilizing a ?ber-optic probe, the method may include the 
initial step of introducing the probe into an artery of a patient 
in combination With a coronary catheter. A NdzYAG 
pumped KTP/OPO tunable near-IR laser system may be 
utilized as a light source for the ?ber-optic catheters and 
related methods disclosed herein. The BEST algorithm may 
be used to construct chemical-composition images of the 
intima of the aorta in test subjects in vivo. 
It is another object of the invention to provide methods 
and apparatus using near-IR spectrometric imaging to non 
destructively locate and identify pools of LDL cholesterol 
Which may serve as an in vivo marker for vulnerable 
atherosclerotic plaques. Vulnerable plaques are thought to 
usually contain a sizable lipid pool containing LDL covered 
by a thin ?brous cap. Near-IR imaging spectrometry may be 
performed as prescribed herein to measure the size and the 
chemical composition of the ?brous cap and the lipid pool. 
An accurate measurement of lipoprotein cholesterol is a 
useful ?rst step in the intervention against diseases such as 
atherosclerosis and ischemic stroke, and is important in 
determining What constitutes a vulnerable plaque in order to 
derive an effective means for stabilizing such plaque. 
Because cholesterol is carried in lipoprotein particles that 
differ in size and apolipoprotein composition, this variety of 
lipoproteins often make non-destructive differentiation of its 
composition dif?cult in the living vessel Wall. As a result, 
most studies focus on in vitro methodologies for determi 
nation of plaque lipoprotein composition. HoWever, produc 
tion of artifacts is common using in vitro methods and has 
lead to confusion in the literature. At present, there is no in 
vivo assay for LDL and forms of oxidized LDL (oxLDL) in 
solid tissue atherosclerotic plaques. More speci?cally, there 
is currently no accurate non-destructive in vivo reference 
assay for LDL or apolipoproteins immobilized in the Walls 
of living human arteries. Chemical analysis of lesions in 
vivo Would provide for the kinetic characterization of 
atherogenesis Which contribute to the understanding of 
lesion formation and groWth. HoWever, the near-IR spec 
trometry of plaque in vivo as described herein may thus 
facilitate assignment of patients to speci?c neW drug inter 
ventions that may affect the course of atherosclerosis (such 
as TPA, Which acts to block thrombi, Enlimomab, Which acts 
to block granulocyte adhesion to the blood-vessel Wall, 
Citicoline, Which reduces free fatty acids, Lubeluzole, Which 
interferes With the effects of nitric oxide, Tirilizad, Which 
acts as a free-radical scavenger, or bFGF, Which acts on 
groWth factors) and/or surgical interventions such as bypass 
grafts or angioplasty and stents. The basic near-IR imaging 
techniques provided herein are based at least in part on the 
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principle that many organic molecules absorb light in the 
near-IR spectrum in a speci?c manner. This creates unique 
re?ectance spectra that can be analyzed to perform a non 
destructive chemical analysis of tissue either through a 
microscope, or at a distance through a ?ber-optic catheter. A 
NdzYAG-pumped KTP/OPO laser system may be used With 
spectrometric catheters for use in analyzing atherosclerosis 
and markers of vulnerable plaque. The near-IR spectromet 
ric catheter may be thus used for early detection of LDL 
uptake in the arterial Wall even before the appearance of 
visible fatty streaks. Another object of the invention there 
fore is to provide near-IR laser spectrometric assays of 
plaque Which may be performed With cardiac catheters in 
vivo to facilitate the assignment of patients to speci?c drug 
or surgical interventions that are selected to match their 
individual vulnerable plaque characteristics. 
Other aspects of the invention are directed to the role of 
group V secretory phospholipase A2 (sPLA2), an important 
enZyme in in?ammatory processes, in the generation of 
vulnerable atherosclerotic plaques. Near-IR imaging may be 
used to identify predetermined compounds such as sPLA2, 
and to survey for neW compounds. For example, lysophos 
phatidylcholine (LPC) is a major product of sPLA2 action. 
Since there are no speci?c antibodies to LPC that could be 
used for immunohistochemical studies, its localiZation in 
various regions of plaque may be determined by near-IR 
imaging of histologic sections. Moreover, near-IR spectra 
may be obtained for lesions from animal studies overex 
pressing sPLA2 activity. These spectra, Which may re?ect a 
combination of elements potentially associated With 
vulnerability, can be compared With the spectra obtained in 
patients at sites proven to be vulnerable by occurrence of 
subsequent events. Spectra from the animal studies may thus 
identify a compound not yet suspected to be associated With 
vulnerability in humans. The role of serum amyloidA(SAA) 
has been also shoWn to be an important cofactor for sPLA2 
activity, and associated With clinical events. Its role may be 
further elucidated by the invention, and Will be measured in 
patients undergoing near-IR imaging. The overall impor 
tance of sPLA2 as a determinant of plaque vulnerability may 
be further recogniZed if sPLA2 is indeed determined to play 
a major role in this condition. An sPLA2 inhibitor may be 
thus used as ?rst-line therapy for patients found to have a 
vulnerable plaque. In any event, the ?nal decision on therapy 
in patients Will be made on the basis of the best information 
available at the time of treatment. The invention provides an 
increased understanding as to the diagnosis, and treatment, 
of vulnerable coronary plaques. This information concern 
ing sPLA2 may provide neW therapeutic opportunities such 
as the development of a speci?c inhibitor of the isoform of 
the enZyme located in macrophages. The development of a 
loW-risk method to identify vulnerable plaques in high-risk 
patients undergoing PTCA/stenting Would greatly aid in the 
conduct of studies to diminish that risk With speci?c drug 
therapy. Individuals at increased risk of disruption of a 
vulnerable plaque may be assisted by the invention Which 
creates the foundation for the development of interventions 
that prevent the sudden onset of a catastrophic coronary 
event. 
It is another object of the invention to provide near-IR 
imaging of plaque composition and vulnerability in vivo. 
Near-IR spectroscopy may identify vulnerable lesions in the 
coronary arteries of living patients. In particular, vulnerable 
coronary plaque may be detected because of the unique 
advantages provided by the catheter-based near-IR imaging 
systems described herein despite the general dif?culty in 
imaging coronary lesions. These catheter-based near-IR 
15 
25 
35 
40 
45 
55 
65 
10 
imaging systems provide possible prospective identi?cation 
of vulnerable coronary artery plaques in living patients. 
Particular investigations may be conducted in accordance 
With the invention: to obtain additional calibration and 
blinded validation of near-IR imaging in ex vivo human 
autopsy specimens (blocks from aortas and coronary 
arteries); to test the ability of catheter-based near-IR imaging 
to detect vulnerable aortic plaque in vivo (in rabbits) With 
diet-induced atherosclerosis; to perform near-IR catheter 
based mapping of coronary artery chemical composition in 
patients undergoing PTCA and/or stenting; and to identify 
rapid lesion progression by angiography and clinical events 
during subsequent years. When potentially high-risk patients 
are identi?ed With near-IR signatures of plaques With lipid 
pools and thin caps, for example, they may be subject to a 
further therapy study to stabiliZe vulnerable plaques. 
Another object of the invention is to thus provide therapeutic 
methods and apparatus to stabiliZe plaques that have been 
characteriZed as vulnerable by using near-IR therapy to 
promote ?brosis or thickening of the thin ?brous caps 
covering these lipid pools to prevent their rupture or leakage. 
The subsequent treatments to be administered may further 
include an orally active matrix metalloproteinase inhibitor 
(MMPI), and, possibly, an inhibitor of Group v secretory 
phospholipase 2 (sPLA2). Patients may also be selected for 
intensive lipid loWering therapies if they Were found to have 
vulnerable plaques. 
In accordance With another aspect of the invention, it is 
further possible to determine the relationship betWeen the 
prospective near-IR chemical map of the human coronary 
tree, and the rapid progression of coronary lesions as of 
one-year later Which may be documented by angiographic 
and/or autopsy ?ndings. These ?ndings may be provided 
from a study involving a relatively large number of patients 
such as 600 or more undergoing angioplasty Wherein three 
major coronary arteries are scanned for the presence of 
vulnerable plaques as described herein. There may be 
folloW-up procedures for up to several years to determine 
the occurrence of subsequent cardiac events. The near-IR 
signature of sites or lesions that eventually progress to an 
event may be considered the near-IR sign or indicator of 
plaque vulnerability. This relationship may be used to con 
struct a near-IR index of true vulnerability of coronary 
plaques in living patients. Various embodiments of the 
invention make this particularly feasible in that near-IR 
spectroscopy may identify plaques With a lipid pool and thin 
cap in vivo, and may be performed through a coronary 
catheter as described herein. Avalidated, prospective, near 
IR index of vulnerability may be thus developed in accor 
dance With the invention. Effective stabiliZation therapy may 
be identi?ed thereafter, and may be Widely used in the 
treatment of high-risk patients undergoing coronary inter 
ventions. Collagen degradation by MMPs and plaque 
in?ammation have been demonstrated in atherosclerotic 
tissue, and Well-tolerated, orally active inhibitors are also 
available. Studies of plaque stabiliZation in such patients 
may further yield information of great value for all indi 
viduals at risk of plaque disruption and coronary events. 
Additional objects and advantages of the invention Will 
become apparent to those skilled in the art upon examination 
of the foregoing description of the invention Which may be 
modi?ed Without departing from the scope of the invention. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 provides an illustration of the near-IR spectrum for 
cholesterol. 
FIG. 2 provides an illustration of the near-IR spectrum for 
lysophosphatidylcholine (LPC). 
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FIG. 3 provides an illustration of the near-IR spectrum for 
a ?brous cap associated With vulnerable plaques. 
FIG. 4 illustrates the spectrum for rat aortas through 
Whole blood and saline. 
FIG. 5 illustrates the spectrum for polystyrene through a 
rat aorta. 
FIG. 6 is an illustration of a near-IR catheter used in vivo 
shoWn While illuminated With a HeNe laser Where light can 
be seen returning doWn a receiving optical ?ber from the 
catheter tip When the catheter is held against an optical table. 
FIG. 7 illustrates a catheter laid beside the heart and aorta 
of a rabbit, and a meter stick Wherein a suture is tied on the 
catheter at the point of maximum insertion to enable the 
penetration to the aortic arch to be determined by measuring 
the distance betWeen the suture and the femoral artery at 
each location Where spectra may be obtained. 
FIG. 8 shoWs the average near-IR spectra from a 1-cm 
aorta segment of a control and a cholesterol-fed rabbit 
Wherein the solid lines represent spectra of the control aorta, 
and the dot-dashed lines represent the spectra of the 
cholesterol-treated aorta. 
FIG. 9 provides a representative frame from a control 
video clip Where increased LDL uptake is represented as a 
darker gray color. 
FIG. 10 provides a representative frame from a 
cholesterol-fed video clip Where increased LDL uptake is 
represented as a darker gray color. 
FIG. 11 provides a data table for the identi?cation vul 
nerable plaque characteristics in humans by near-IR imag 
mg. 
FIG. 12 illustrates the spectra of a lipid pool and ?brous 
cap associated With human vulnerable plaque. 
FIG. 13 is a simpli?ed representation of one embodiment 
of the apparatus provided by the invention that includes a 
compound parabolic concentrator for the analysis of tissue. 
FIG. 14 is a simpli?ed representation of another embodi 
ment of the invention that includes an inverted, substantially 
cone-shaped re?ector. 
FIG. 15 is a distal end vieW of a ?ber-optic bundle used 
in apparatus provided by the present invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides methods and apparatus for 
in vivo detection and characteriZation of vulnerable athero 
sclerotic plaques With near-infrared (IR) spectroscopy. Each 
of the disclosed embodiments may be considered individu 
ally or in combination With other variations and aspects of 
the invention. The near-IR spectrometric imaging tech 
niques described herein may be used to non-destructively 
locate and identify loW-density lipoprotein (LDL) choles 
terol Which may serve as an in vivo marker for the presence 
of vulnerable atherosclerotic plaques. Vulnerable plaques 
may be generally described as plaques that are prone, With 
or Without a triggering activity or event of a patient, to 
events such as ulceration, rupture, erosion leading to throm 
bosis causing an acute syndrome. The characteriZation and 
risk assessment of clinical patients using near-IR laser 
spectrometric assays of vulnerable plaque in vivo may 
enable the assignment of patients to speci?c drug or surgical 
interventions selected to match individual plaque character 
istics. 
I. Applications for in vivo Identi?cation and CharacteriZa 
tion of Vulnerable Plaque 
The invention provides methods and apparatus for the 
identi?cation and characteriZation of vulnerable plaques, 
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particularly in coronary circulation, that may be readily 
implemented as part of an early detection and intervention 
program. 
A. Prospective Identi?cation of the Vulnerable Plaque 
In general, a plaque that is formed With a large lipid pool, 
a thin ?brous cap and macrophage in?ltration, is a plaque 
that may be considered vulnerable to disruption (Muller J E, 
Kaufmann P G, Luepker R V, Weisfeldt M L, DeedWania P 
C, Willerson J T, Mechanisms precipitating acute cardiac 
events: RevieW and recommendations of an NHLBI 
Workshop, National Heart, Lung, and Blood Institute: 
Mechanisms Precipitating Acute Cardiac Events 
Participants, Circulation 1997; 96(9):3233—9 (cited refer 
ences are incorporated herein by reference)). While lipid and 
macrophage-laden plaques are vulnerable to disruption, it is 
important to recogniZe the incomplete nature of the basis for 
supporting this hypothesis. Although large lipid pools and 
thin caps With macrophages have been identi?ed in dis 
rupted plaques, a prospective study has not been conducted 
to demonstrate that these features are predisposed to disrupt, 
even in an animal model. Also, such microanatomy does not 
account for the plaques that erode and produce thrombosis. 
HoWever, the concepts of the present invention are directed 
to the identi?cation and characteriZation of certain lesions 
(plaques With lipid pools and thin, Weakened caps, or some 
other features) that are particularly vulnerable to disruption. 
These types of vulnerable plaques have been detected and 
identi?ed prior to disruption, in part, by folloWing the 
patients until a suf?cient number of coronary events 
occurred (Uchida et al, Prediction of acute coronary syn 
dromes by percutaneous coronary angioscopy in patients 
With stable angina, Amer Heart J 1995, 130 (2): 195—203). 
The events occurred With greater frequency at sites sus 
pected to be vulnerable than at non-vulnerable sites. Given 
the present state of knoWledge, and for purposes of avoiding 
confusion herein, the term vulnerable may describe the 
pathologic ?ndings of a plaque having a large lipid pool, a 
thin cap, and an in?ammatory in?ltrate (Muller J E, Abela G 
S, Nesto R W, To?er G H, Triggers, acute risk factors and 
vulnerable plaques: The leXicon of a neW frontier, J Am Coll 
Cardiol 1994; 23:809—13). Vulnerable may also refer to 
plaques that may be identi?ed in the future With near-IR 
imaging in accordance With the invention that also lead to a 
higher rate of events. A subset of plaques shoWn to be 
vulnerable by near-IR With supporting outcome data may be 
further characteriZed as vulnerable plaques as de?ned by 
histology. In any event, the identi?cation of vulnerable 
plaques prior to disruption as described herein provides an 
enormous advantage in the prevention of cardiovascular 
disease, and further provides an opportunity to effect appro 
priate treatment Which Would convert such plaques to non 
vulnerable plaques. 
B. Near-IR Imaging For Identifying Vulnerable Coronary 
Plaques 
The invention provides methods and apparatus to identify 
vulnerable coronary plaques in patients With near-IR spec 
trometry. These techniques are based on the absorbance of 
light in the near-IR spectrum, in a speci?c manner, by 
organic molecules. This creates unique re?ectance spectra 
that can be used to obtain a chemical analysis of tissue in a 
non-destructive manner. 
1. Features of Near-infrared Spectrometry. 
The near-IR region of the electromagnetic spectrum, once 
regarded as having little potential for analytical Work, has 
become one of the most promising for molecular spectrom 
etry. The advent of inexpensive and poWerful computers has 
further contributed to the surge of neW near-IR spectrometric 
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applications. The near-IR region is usually estimated to 
include Wavelengths betWeen 700 nm (near the red end of 
the visible spectrum) and 3000 nm (near the beginning of 
infrared stretches of organic compounds). Absorbance peaks 
in the near-IR region originate from overtones, from com 
binations of the fundamental (mid-IR) bands and from 
electronic transitions in the heaviest atoms. For example, 
C—H, N—H, and O—H bonds are responsible for most 
major absorbance peaks observed in the near-IR spectrum, 
and near-IR spectrometry is used chie?y for identifying or 
quantifying molecules that contain unique hydrogen atoms. 
Near-IR spectrometry is therefore used routinely for quan 
titative analyses of Water, alcohols, amines, and any com 
pounds comprising C—H, N—H, and/or O—H groups. It 
has been also used industrially for a number of years to 
determine the sites and amount of saturation in unsaturated 
fatty acid esters (WetZel D, Near-infrared re?ectance analy 
sis: Sleeper among spectroscopic techniques, Anal Chem 
1983; 1165A—76A). In addition, near-IR spectrometry is 
characteriZed by loW molar absorptivities and light scatter 
ing Which permit conservation of time and materials in 
comparison to more conventional analytical methods 
because of various reasons including: 1) analysis times 
under one second are possible; 2) simultaneous multi 
component analysis is the norm; 3) no sample preparation is 
usually required for liquids, solids, or gases; 4) non-invasive 
and non-destructive analysis is possible; 5) the cost-per 
analysis is very loW (no reagents are used); 6) physical 
properties and biological effects can be calculated from 
spectra of samples; 7) automated correction of background 
and interferences is performed in instruments using com 
puter algorithms; 8) detection limits can be very loW; 9) 
samples siZes ranging “from picograms to planets” can be 
analyZed; and 10) molecular structural information can be 
derived from spectra. 
2. Technical Aspects of Near-IR Imaging 
Near-IR spectrometry typically uses a tunable light source 
(?lter Wheel, monochromator, interferometer or laser) exter 
nal to the experimental subject to determine the chemical 
composition of a sample. Detectors can be single elements 
for spectrometry, or may be detector arrays in cameras for 
spectrometric imaging. Modem near-IR spectrometers and 
sampling techniques have improved to the point that it is 
possible to analyZe intact ?nished pharmaceutical products, 
and even analytes in living human patients. In vivo near-IR 
spectrometry had been plagued historically by problems 
With high Water absorbance in tissue, light scattering, peak 
overlap, and peak shifting With temperature and sample 
matrix composition. HoWever, more intense and more stable 
light sources, more ef?cient detectors (and in many cases, 
more ef?cient imaging detectors), and improved methods of 
obtaining rapid Wavelength selectivity have permitted appli 
cation of near-IR imaging to increasingly complex biologi 
cal and medical problems. The importance of these instru 
mental advances is evident in the application of near-IR 
spectrometry to atherosclerosis and stroke research. Using a 
specially modi?ed IR video camera, different band pass 
?lters or tunable lasers permit collection of image spectra 
over the range of 1000—4000 nm (near-IR and IR spectral 
range) (Dempsey R J, Davis D G, Buice R G, Lodder R A, 
Biological and medical applications of near-infrared 
spectrometry, Appl Spectrosc 1996; 18A—34A). 
3. Methods of UtiliZing Near-IR Imaging 
a) Identi?cation of speci?c compounds 
A major advantage of using near-IR spectrometric imag 
ing over ultrasonic and magnetic resonance imaging (MRI) 
is its ability to perform simultaneous, multi-component 
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chemical analyses With a single near-IR spectral scan. The 
near-IR spectrum of a sample, Which is generated from 
combinations and harmonics of fundamental molecular 
motions, contains more chemically speci?c information than 
is ordinarily available in an ultrasonic absorbance spectrum. 
At the same time, the large number of near-IR 
chromophores, and the intrinsically high signal-to-noise 
ratio (S/N) of near-IR instruments, give near-IR spectrom 
etry improved sensitivity to lipids and collagens in samples 
such as vulnerable coronary artery plaques, as described 
herein, than is available through MRI. Near-infrared spec 
trometry has been used to identify thousands of chemicals, 
including such biologically interesting analytes as 
cholesterol, HDL, and LDL (Cassis L A, Lodder R A, 
Near-IR imaging of atheromas in living arterial tissue, 
Analytical Chem. 1993; 65(9):1247—56), glucose and albu 
min (Drennen J K, Gebhart B D, Kraemer E G, Lodder R A, 
Near-infrared spectrometric determination of hydrogen ion, 
glucose, and human serum albumin in a simulated biological 
matrix, Spectroscopy 1990; 28—36). 
b) Identi?cation of Spectral Difference BetWeen Different 
Types of Complex Tissues 
Near-infrared spectrometry has been used for measure 
ment of cerebral oxyhemoglobin and deoxyhemoglobin in 
adults (ElWell C E, Matcher S J, TysZcZuk L, Meek J H, 
Delpy D T, Measurement of cerebral venous saturation in 
adults using near infrared spectroscopy, Adv Exp Med Biol 
1997; 411:453—60). Non-invasive near-IR spectrophotom 
etry of gerbil brain tissue in vivo has been shoWn to 
discriminate betWeen adult (three to four months of age) and 
aged (18 to 20 months of age) brains, as Well as betWeen 
brains exposed to ?ve and ten minutes of ischemia (Carney 
J M, Landrum W, Mayes L, Zou Y, Lodder R A, Near-IR 
spectrophotometric monitoring of stroke-related changes in 
the protein and lipid composition of Whole gerbil brains, 
Anal Chem 1993; 1305—13). It has been also used transar 
terially in the carotid arteries of human patients to identify 
?brous caps, lipids, thrombus, ulceration and necrosis With 
an indium antimonide focal plane array video camera. 
Inverse principal axis transformation revealed the linear 
combination of lipoproteins that correlated to necrosis in the 
plaque pathology reports (nc=29 patient plaques for 
calibration, nv=29 patient plaques for cross validation). The 
data Were normaliZed by Z-scoring, so a ?at line at y-axis=0 
represented the average gel appearance. Positive deviations 
from y=0 represented more protein in the molecular mass 
region than the average gel, While negative deviations rep 
resent less protein in the molecular mass region than the 
average gel. Amaj or difference betWeen the necrotic plaques 
and the plaques Without necrosis is the presence of a 128 KD 
lipoprotein in the necrotic plaques. 
4. Potential Advantages of Near-IR for Identifying Vul 
nerable Coronary Plaques 
The methods and apparatus provided herein for identify 
ing and characteriZing vulnerable coronary plaques demon 
strate effective chemical sensitivity and speci?city. As 
described above, a major advantage of near-IR spectrometric 
imaging over ultrasonic and MRI is its ability to perform 
simultaneous multi-component chemical analyses using a 
single near-IR spectral scan. Moreover, near-IR spectrom 
etry can be implemented in a catheter as described herein 
Which are even smaller than those devices used in ICUS, and 
permit high resolution (both spatial and chemical) analyses 
to be performed Within arterial vessels of living patients. The 
cost of catheters described herein may be relatively loW 
enough to make them disposable, single-use devices. The 
high intensity and tunability of external cavity tunable diode 
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lasers also makes intravascular near-IR imaging a durable 
and relatively inexpensive solution. The rapidity of high S/N 
spectral data collection further enables complete chemical 
maps of blood vessels like coronary arteries to be readily 
obtained during an interventional PTCA. The invention thus 
provides an accurate non-destructive in vivo reference assay 
for most lipids and proteins immobilized in the Walls of 
living human arteries. In addition to detecting vulnerable 
plaque, chemical analysis of lesions in vivo may be accom 
plished Which may further the kinetic study of atherogenesis 
and contribute to the understanding of lesion formation and 
groWth. The methods and apparatus described herein may 
play key roles in the monitoring the progression or regres 
sion of, the vulnerability of lesions. Near-IR spectrometry of 
plaque in vivo may facilitate assignment of patients and 
plaques to speci?c neW drug interventions that affect the 
course of atherosclerosis. Better treatment programs may be 
thus designed that focus on these mechanisms. 
C. Clinical Issues 
1. Prognosis of Post-PTCA/Stenting 
The near-IR imaging described herein may be performed 
on patients undergoing PTCA/stenting Who Will already 
have a Wire inserted in a culprit artery for clinical reasons. 
Arationale for near-IR imaging in these patients may be that 
during the folloWing year folloWing PTCA/stenting, 
approximately 10% Will experience death, myocardial inf 
arction (MI), or require repeat revasculariZation because of 
rapid progression of a plaque other than the one originally 
treated. It is the progression of such plaques that has 
substantially led to the inability of PTCA/stenting and 
CABG to prevent subsequent MI in randomiZed studies. 
2. Therapy to Stabilize Vulnerable Plaques 
Different therapies have been developed thus far for 
stabiliZing vulnerable plaques. These and future treatments 
may be carried out in light of the bene?ts conferred by the 
invention as described herein. 
a) Lipid Lowering 
In contrast to the experience With revasculariZation, 
intense lipid loWering With statins has been found to prevent 
MI. The observation that the degree of prevention of MI 
exceeded the modest improvements in ?xed stenoses, has 
led to some speculation that the therapy stabiliZed vulner 
able plaques. While this may occur, even When lipid loW 
ering therapy is administered maximally, the event rate for 
this group remains high, and additional therapies are still 
generally needed. 
b) Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a group of pro 
teolytic enZymes that can digest collagen and elastin in the 
extracellular matrix. Several studies have identi?ed MMPs 
in animal and human vulnerable plaques. The MMPs Within 
plaques are believed to be secreted by activated macroph 
ages (Matrisian L M, The matrix degrading 
metalloproteinases, Bioessays 1992; 14:455—63) and to be at 
least in part responsible for extracellular matrix degradation 
leading to Weakening of plaques ?brous cap, and plaque 
rupture With its clinical sequelae (Henney A M, Wakeley P 
R, Davies M J et al, LocaliZation of stromelysin gene 
expression in atherosclerotic plaques by in situ 
hybridiZation, Proc Natl Acad Sci USA 1991; 88:8154—8). 
Thickness and collagen content of the ?brous cap are 
important for the stability of the plaque (Loree H M, Kamm 
R D, StringfelloW R G, Lee R T, Effects of ?brous cap 
thickness on peak circumferential stress in model athero 
sclerotic vessels. Circ Res 1992, 71, 850—858). The plaque 
disruption occurs most frequently at sites Where the ?brous 
cap is the thinnest and the most heavily in?ltrated by foam 
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cells (Friedman M, The coronary thrombus: Its origin and 
fate, Hum Pathol 1971; 2:81—128). The release of pro 
teolytic enZymes, in particular MMPs, by these cells has 
been suggested as a mechanism leading to plaque vulner 
ability and rupture (Richardson P D, Davies M J, Born G V, 
In?uence of plaque con?guration and stress distribution in 
?ssuring of coronary atherosclerotic plaques, Lancet 1989; 
2:941—4; Davies M J, Richardson P D, Woolf N, KatZ D R, 
Mann J, Risk of thrombosis in human atherosclerotic 
plaques: Role of extracellular lipid, macrophage and smooth 
muscle content, Br Heart J 1993; 69:377—81; Seppo T, Kevin 
D, Marina F et al, Interstitial collagenase expression in 
human carotid atherosclerosis, Circulation 1995; 
92:1393—8; Zorina G, Galina S, Roger K, Stephen C, Libby 
P, Macrophage foam cells from experimental atheroma 
constitutively produce matrix-degrading proteinases, Proc 
Natl Acad Sci USA 1995; 92:402—6). MMPs have also been 
found to be active in spread of tumors (Stetler-Stevenson 
WG, Liotta LA, Kleiner D E, Extracellular matrix 6: Role 
of matrix metalloproteinases in tumor invasion and 
metastasis, FASEB J 1993; 7:1434—41; BroWn P, GiavaZZi 
R, Matrix Metalloproteinase inhibition: A revieW of anti 
tumour activity, Annal of Onc 1995; 6:967—74) and other 
conditions such as rheumatoid arthritis (Yoshihara Y, Obata 
K, Fujimoto N, Yamashita K, HayakaWa T, Shimmei M, 
Increased levels of stromelysin-1 and tissue inhibitor of 
metalloproteinases-1 in sera from patients With rheumatoid 
arthritis, Arthritis Rheum 1995; 38:969—75), osteoarthritis 
(Manicourt D H, Fujimoto N, Obata K, Thonar E J, Serum 
levels of collagenase, stromelysin-1, and TIMP-1, Age and 
sex related differences in normal subjects and relationship to 
the extent of Joint involvement and serum levels of antigenic 
keratin sulfate in patients With osteoarthritis, Arthritis 
Rheum 1994; 37: 1774-83), liver cirrhosis (Takahara T, Furui 
K, Funaki J et al, Increased expression of matrix 
metalloproteinase-II in experimental liver ?brosis in rats, 
Hepatology 1995; 21:787—95), Crohn’s disease and emphy 
sema (Shapiro S D, Elastolytic metalloproteinases produced 
by human mononuclear phagocytes, Potential roles in 
destructive lung disease, Am J Respir Crit Care Med 1994; 
150:S160—S164). 
Activity of MMPs in tissue is regulated at many levels. 
Initially, their expression is modulated at the gene level, and 
moreover, they are secreted in proenZyme form and require 
activation. Further modulation is primarily achieved by a 
balance betWeen enZyme concentration/activity and nonspe 
ci?c (2-macroglobulin) and speci?c (tissue inhibitors of 
metalloproteinases -TIMPS) inhibitors. In addition to natu 
rally occurring inhibitors, a number of designed inhibitors 
have been developed, and are in different phases of testing 
for their investigational and clinical utility. Most of the 
human studies to date are at the stage of phase I/II clinical 
trials. The safety pro?le of synthetic MMPs inhibitors in 
therapy of prostate, lung, colon and breast malignancies is 
satisfactory. Agouron Pharmaceuticals Inc., for example, has 
designed and produced several MMP inhibitors (MMPI). 
One inhibitor has thus far demonstrated relatively poWerful 
activity against stromelysin, and has been quite Well toler 
ated in over 150 patients With prostate cancer. At the present 
time, there are no knoWn published studies relating to the 
use of natural or synthetic MMPIs to inhibit plaque disrup 
tion and/or accelerate transition to mature, stable, dormant 
plaque. HoWever, in experimental ex vivo models involving 
human atherosclerotic plaques and activated macrophages, 
MMP inhibitors have been shoWn to substantially decrease 
extracellular matrix degradation. In summary, MMPs may 
be indeed involved in plaque vulnerability, and Well 
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tolerated inhibitors are presently available for human studies 
Which may be used in accordance With the principles of the 
invention. 
c) sPLA2 inhibitors 
While the role of sPLA2 in vulnerability has not received 
as much attention as MMPs, this enZyme and the products 
it creates, may play a role in weakening plaque, perhaps at 
a more basic level. Further research may clarify its role, and 
if it is active, inhibitors for clinical use may be also obtained 
and used in combination With other aspects of the invention. 
D. Early Detection and Characterization of Vulnerable 
Plaque 
Although the procedures and apparatus provided herein 
may detect vulnerable coronary plaques to help identify 
groups at higher risk, most individuals actually experience 
their ?rst MI and/or a coronary death prior to their ?rst 
catheteriZation. Signi?cant bene?ts may be still achieved 
nonetheless if the invention Were directed to a sample subset 
of 400,000 patients Who undergo PTCA/stenting. The treat 
ment for this group of the population may lead to less 
invasive means of detection and treatment that are appli 
cable to the much larger group of individuals With knoWn 
coronary artery disease (CAD), or are at high risk for CAD. 
In accordance With the principles of the present invention, 
near-IR mapping may be performed With these patients Who 
may undergo diagnostic catheteriZation for purposes of 
comparison to established a near-IR vulnerability index. The 
procedure may be highly predictive of subsequent events, 
and may offer safe and ef?cacious treatment for identi?ed 
plaque vulnerability in subsequent cases. 
II. Preliminary Studies and Discussion 
The folloWing section is a description of near-IR imaging 
studies in laboratory settings that included various applica 
tions for the methods and apparatus provided in accordance 
With the principles of the invention. 
A. Near-IR Spectrometry 
1. Near-IR Analytes Measured In vitro 
The invention incorporates technology relating to near-IR 
of analytes measured in vitro including quantitative and 
qualitative near-IR spectrometry of cholesterol, cholesterol 
esters, cholesterol monohydrate, and lipoprotein cholesterol 
in blood serum and in plaques (Cassis LA, Yates J, Symons 
W C, Lodder R A, Cardiovascular near-infrared imaging, J 
Near-Infrared Spectrosc 1998; Lodder R A, Moorehead W, 
Robertson S P, Rand PHGM, Assessment of the Feasibility 
for Determination of Cholesterol and Other Blood Constitu 
ents by Near-Infrared Re?ectance Analysis, Talanta 1989; 
36:193—8). The spectrum of cholesterol has unique identi 
fying features in a so-called Water WindoW Where Water has 
minimal absorbance (i.e., no vibrational energy absorbance 
peaks) betWeen about 1450 and 1950 nm as shoWn in FIG. 
1. These absorbance-Wavelength features may be used to 
identify and quantify cholesterol simultaneously With other 
components in mixtures. Because light scattering decreases 
With the fourth poWer of Wavelength, and because this 
spectral region is far removed from the hemoglobin elec 
tronic absorbance that lies beloW 1000 nm, light penetration 
through Whole blood is typically very good. As shoWn in 
FIG. 2, lysophosphatidylcholine (LPC) also has a unique 
near-IR spectrum that can be used to detect the activity of 
sPLA2 in in?ammatory processes. The near-infrared diffuse 
re?ectance spectrum of collagens may be used to detect the 
presence of ?brous caps on vulnerable plaques, and to 
determine the siZe of the cap With near-infrared imaging as 
shoWn in FIG. 3. 
2. Near-IR Imaging through Whole Blood 
Near-IR light in the 1600—1900 nm Wavelength region 
penetrates suf?ciently through Whole blood to enable spec 
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troscopy Within blood vessel Walls as shoWn in FIG. 4 
(Cassis LA, Lodder R A, Near-IR imaging of atheromas in 
living arterial tissue, Analytical Chem. 1993; 65(9) 
:1247—56). Fiber-optic probes and a monochromator system 
With a 1000 W tungsten-halogen lamp Was used to obtain 
spectra of the aortas of rats. The natural reduction in 
scattering of light in this long Wavelength region and the 
reduced absorbance of Water in this Water WindoW, com 
bined to permit the collection of good-quality spectra In 
general, the ?ber-optic probe may be operated relatively 
close to the vessel Wall (<1 mm) to minimiZe interference 
from Whole blood. Spectra of the aorta may be obtained 
through both Whole blood and phosphate-buffered saline 
(PBS) as demonstrated in FIG. 4, and are shoWn With solid 
and dashed lines. The spectra are virtually identical and 
overlap over most of the Wavelength range examined. 
In a further test of the penetration ability of near-IR light, 
the spectrum of a polystyrene Wavelength-calibration stan 
dard may be obtained through a rat aorta as shoWn in FIG. 
5 (Cassis LA, Lodder R A, Near-IR imaging of atheromas 
in living arterial tissue, Analytical Chem. 1993; 65(9) 
:1247—5 6). The spectrum of the polystyrene may be obtained 
trans-arterially by transmitting the light from a ?ber-optic 
probe placed on the outside of the aorta, through both Walls 
of the aorta, then through the polystyrene, re?ected back off 
a mirror, and back through the polystyrene and both Walls of 
the aorta to the detector. The total path length Was 4 mm, 
Which is generally deeper than a human coronary plaque. 
FIG. 5, depicts three spectra: the loWest (the spectrum of the 
polystyrene standard alone), the middle (someWhat feature 
less spectrum is the spectrum of the aorta), and the upper 
spectrum (the spectrum of the polystyrene obtained through 
the aorta). The spectral absorbance peaks of polystyrene 
shoW through Well in the 1100—1300 nm and 1600—1850 nm 
Wavelength regions. The largest peaks of polystyrene (the 
triplet at 2140—2200 nm) may even shoW through someWhat. 
although they may be greatly diminished by the large 
background absorbance of Water. 
3. Imaging the Rabbit Aorta Through a Catheter 
Some of the studies described herein Were conducted 
using the atherosclerotic rabbit model introduced by Con 
stantinides et al. (Constantinides P, Chakravarti R N, Rabbit 
arterial thrombosis production by systemic procedures, Arch 
Pathol 1961; 72:197—208). This rabbit model develops vul 
nerable plaques prone to rupture With subsequent thrombosis 
(Abela G S, Picon P D, Friedl S E et al, Triggering of plaque 
disruption and arterial thrombosis in an atherosclerotic rab 
bit model, Circ 1995; 91:776—84). The plaque generation 
feature of the model (not the triggering aspect) Was used to 
test the near-IR catheters provided herein. In the imaging of 
rabbit aortas, a NdzYAG-pumped KTP/OPO laser system 
Was used to test experimental spectrometric catheters devel 
oped for use in several projects investigating atherosclerosis 
and markers of vulnerable plaque. The purpose of this 
experiment Was to test the hypothesis that a near-IR spec 
trometric catheter is capable of early detection of cholesterol 
uptake in the arterial Wall through Whole blood even before 
the appearance of visible fatty streaks. The light source used 
in the catheter experiments Was a laser system consisting of 
a MIRAGE 3000B Mid-Infrared Optical Parametric Gen 
erator and a Continuum NY81—10 NdzYAG Pump Laser. 
The system provides tunable near-IR light With a Wave 
length from 1.4 to 4.1 micrometers and an effective poWer 
of 3.3 million Watts. The spectra Were scanned in the Water 
WindoW betWeen 1650 and 1780 nm, Where LDL cholesterol 
is generally knoWn to have tWo major peaks. The catheters 
Were constructed in-house from communications-grade opti 











